December 8, 2025December 8, 2025 Shares of Biocon Ltd fell 1% after hitting a day’s high of Rs 395.60 on 8th December, following the company’s announcement that it will convert its subsidiary, Biocon Biologics, into a 100% wholly owned unit. The company said it will…
October 17, 2025October 17, 2025 Shares of Biocon Ltd fell 1% after touching a day’s high of Rs 361.35 on 17th October, despite the company’s subsidiary announcing a multi-year agreement with US non-profit Civica, establishing an exclusive distribution channel to supply affordable insulin and other pharmaceutical products in the…
September 5, 2025September 5, 2025 Shares of Biocon Ltd rose 1% to a day’s high of Rs 364.80 on 5th September, after the company announced that the US Food and Drug Administration (FDA) had completed a routine current Good Manufacturing Practice (cGMP) inspection at Biocon Biologics’ drug substance facility…
Shares of Biocon will remain in focus on Monday, March 10, after the company announced that it has achieved positive results from a phase 3 study that compares Yesintek (Biocon Biologics’ biosimilar to Ustekinumab) with reference products. “Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523,…